Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and ...
📰 Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease - Biogen (Biogen) 🔗 Source: https://news.google.com/rss/articles/CBMiwgFBVV95cUxPX0xNaEdQU1N0eHU4TDJzUnBQWFRMelRMSEFza3ZxN1Nhd2RNclNHb0Q4VkFBeWZxMHd5MDVfaEY2YUNpSkNPeExGYzlmdWNwbWVRNXRpV0pqcDhNX0pXTHZGYnlCWFd5b0pTaW5ZbndKSjJCcmcxOUx6RzYwa0Z0Qm9lRFJoWjVqRU9kcTkwOFBZWmNRTGJLTnZPdEhvaHU4UkJuMnhNVHdzamhhUTR5U2tOWG9kN3FhYmxDelY2ejJFZw?oc=5














